Blogs & News

Huvepharma Announces FDA-Approval for Cattle Feed Additive, Optigrid® 45 (Ractopamine Hydrochloride Type A Medicated Article)

PEACHTREE CITY, GA (May 19, 2020) — Global animal health company, Huvepharma®, has received FDA-approval for Optigrid® 45 (ractopamine hydrochloride), a feed additive used to promote weight gain and improve feed efficiency in finishing feedlot cattle.

Optigrid® 45, which is comprised of the active ingredient ractopamine hydrochloride, is a bio-equivalent product to Optaflexx®. It can be fed as a complete feed or top dress feed to cattle fed in confinement for slaughter during the last 28 to 48 days on feed prior to harvest. When fed as a complete feed, ractopamine hydrochloride can also promote increased carcass leanness.

“In today’s challenging world, with the continued need for efficiency in beef production, we are pleased to bring further medicated feed additive options such as Optigrid® 45 to the cattle industry,” says Glen Wilkinson, president of Huvepharma, Inc. (U.S.).

Wilkinson points out that as an FDA-approved bio-equivalent, Optigrid® 45 provides the same benefits of dosage, chemical identity, potency, quality and safety to the existing ractopamine hydrochloride brand.

“Optigrid® 45 adds another choice from Huvepharma’s expanding product line and is a continued example of our commitment to bring our core strength in medicated feed additives to the U.S. animal food producing industry,” adds Wilkinson. “Huvepharma’s product development, regulatory and sales teams are dedicated to providing effective and essential animal health products to the livestock industry.”

Huvepharma received FDA approval for Monovet® 90 (monensin Type A medicated article) – a bio-equivalent to Rumensin – in July 2019, and has offered animal health products for poultry, swine and cattle in the U.S. since 2005.

Throughout the U.S., Huvepharma is focused on building partnerships with industry customers by offering high quality products and unparalleled customer service. For more information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at 877-994-4883 or visit www.huvepharma.us.

IMPORTANT SAFETY INFORMATION: OPTIGRID® 45 (ractopamine hydrochloride Type A medicated article): Not for human use. For use in feeds for cattle fed in confinement for slaughter. Not for animals intended for breeding. No withdrawal is necessary if directions are followed. The active ingredient in Optigrid 45, ractopamine hydrochloride, is a Beta-adrenergic agonist. Individuals with cardiovascular disease should exercise special caution to avoid exposure. Not for use in humans. Keep out of the reach of children. The Optigrid 45 formulation (Type A Medicated Article) poses a low dust potential under usual conditions of handling and mixing. When mixing and handling Optigrid 45 use protective clothing, impervious gloves, protective eye wear, and a NIOSH-approved dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse eyes
thoroughly with water. If irritation persists, seek medical attention. The Safety Data Sheet (SDS) contains more detailed occupational safety information. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Huvepharma, Inc. at 1-877-994-4883 or www.huvepharma.us. View product label here.

IMPORTANT SAFETY INFORMATION: MONOVET® 90 (monensin Type A medicated article): Not for Human Use. Do not allow horses or other equines access to feeds containing monensin. Ingestion of monensin by horses has been fatal. Consumption by unapproved species may result in toxic reactions and even fatalities. A withdrawal time has not been established for pre-ruminating calves. Do not use in calves to be processed for veal. When mixing and handling Monovet 90, use protective clothing, impervious gloves and a dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse with water. To report adverse effects, access medical information, or obtain additional product information, call 1-877-426-7765. View product label here.

About Huvepharma

Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company headquartered in Sofia, Bulgaria, Huvepharma’s U.S. headquarter are located in Peachtree City, GA. Learn more about Huvepharma and its products at https://huvepharma.us/.

Huvepharma is a registered trademark of Huvepharma EOOD.

Optaflexx and Rumensin are registered trademarks of Elanco U.S. Inc.